The chemotherapeutic efficacy of gentamicin, tobramycin, sisomicin and dioxydin was studied and compared in rats with hematogenic obturation P. aeruginosa pyelonephritis. The drugs were injected intramuscularly in doses of 5, 8, 8 and 50 mg/kg, respectively for 7 days a day after infection. It was shown that on prolongation of the period of the treatment estimation from 24 hours to 7 days after discontinuation of the drug use a significant decrease was observed in the therapeutic efficacy of dioxydin, gentamicin and especially tobramycin. As for sisomicin, the decrease was insignificant. Dioxydin and gentamicin had a similar therapeutic effect at the early and late periods of their estimation after discontinuation of the treatment. They were inferior to tobramycin with respect to the early results and superior to it with respect to the late results. The chemotherapeutic efficacy of sisomycin in both the cases was higher than that of tobramycin, gentamicin and dioxydin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Drugs
October 2024
Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 502 Basic Medical Sciences Building, 745 Bannatyne Avenue, Winnipeg, MB, R3E 0J9, Canada.
Taniborbactam (formerly known as VNRX-5133) is a novel bicyclic boronate β-lactamase inhibitor of serine β-lactamases (SBLs) [Ambler classes A, C, and D] and metallo-β-lactamases (MBLs) [Ambler class B], including NDM and VIM, but not IMP. Cefepime-taniborbactam is active in vitro against most isolates of carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), including both carbapenemase-producing and carbapenemase-non-producing CRE and CRPA, as well as against multidrug-resistant (MDR), ceftazidime-avibactam-resistant, meropenem-vaborbactam-resistant, and ceftolozane-tazobactam-resistant Enterobacterales and P. aeruginosa.
View Article and Find Full Text PDFInitial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continents.
Transpl Infect Dis
December 2024
Transplant Infectious Disease and Compromised Host Program, Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Background: Despite the burden of pyelonephritis after kidney transplantation, there is no consensus on initial empirical antibiotic management.
Methods: We surveyed clinicians throughout the world on their practice and opinions about the initial empirical therapy of post-transplant pyelonephritis, using clinical vignettes. A panel of experts from 19 countries on six continents designed this survey, and invited 2145 clinicians to participate.
Febrile Immunocompromised Renal Transplant Recipient with Allograft Dysfunction: Detection of an Undiagnosed Prostate Abscess by [ F]FDG-PET/CT along with Treatment Response Monitoring.
World J Nucl Med
September 2024
Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel, Mumbai, Maharashtra, India.
Article Synopsis
- The report details the clinical journey of a 35-year-old male kidney transplant patient suffering from post-transplant fever and suspected acute-on-chronic graft dysfunction with no clear infectious source identified through various diagnostic tests.
- Initial treatments included antibiotics for persistent symptoms, leading to emergency hospitalization due to acute urinary retention, high creatinine levels, and proteinuria.
- Further imaging with [F]FDG-PET/CT revealed prostatitis and abscess complications, but despite improvement in symptoms after treatment, the patient ultimately experienced worsened graft function and required dialysis after eight months.*
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
Antimicrob Agents Chemother
July 2024
Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.
Unlabelled: CERTAIN-1 was a Phase 3, double-blind, randomized, parallel group study of the efficacy and safety of cefepime-taniborbactam versus meropenem in the treatment of adults with complicated urinary tract infection (cUTI), including acute pyelonephritis. We determined susceptibility of Enterobacterales and baseline pathogens to cefepime-taniborbactam and comparators and characterized β-lactam resistance mechanisms. Microbiologic response and clinical response were assessed in patient subsets defined by baseline pathogens that were of cefepime-, multidrug-, or carbapenem-resistant phenotype or that carried β-lactamase genes.
View Article and Find Full Text PDFCefepime/Enmetazobactam: First Approval.
Drugs
June 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Article Synopsis
- Cefepime/enmetazobactam (EXBLIFEP) is a new IV antibacterial medication aimed at treating infections from multi-drug-resistant (MDR) Gram-negative bacteria.
- It was approved in February 2024 in the USA for complicated urinary tract infections (cUTIs) in adults and received EU approval in March 2024 for cUTIs, hospital-acquired pneumonia, and related bacteraemia.
- The article tracks the development journey of cefepime/enmetazobactam leading to its market approval for these serious infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!